Treatment of Hepatitis D — A Future Role for Combination Therapy
New England Journal of Medicine · 2024
DOI: 10.1056/nejme2406180 ↗Kurz gefasst
Editorial in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Norah Terrault. Beteiligte Einrichtung: From the Keck School of Medicine, University of Southern California, Los Angeles. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis D. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Hepatitis D virus (HDV) infection is the most serious form of viral hepatitis, with an accelerated clinical course and heightened risks of cirrhosis and liver cancer. 1 No therapies for HDV infection have been approved by the Food and Drug Administration (FDA), which has made the management of this disease challenging for decades. However, the tide has turned, with several new drugs under study. The goal of therapy is to achieve HDV eradication, with the very best treatment being one that would achieve clearance of both HDV and hepatitis B surface antigen (HBsAg), yielding a functional cure of both HDV and . . .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Keck School of Medicine, University of Southern California, Los Angeles.
Zitieren
APA
Terrault, N. (2024). Treatment of Hepatitis D — A Future Role for Combination Therapy. New England Journal of Medicine. https://doi.org/10.1056/nejme2406180
Vancouver
Terrault N. Treatment of Hepatitis D — A Future Role for Combination Therapy. New England Journal of Medicine. 2024. doi:10.1056/nejme2406180
BibTeX
@article{Terrault2024,
author = {Terrault, Norah},
title = {Treatment of Hepatitis D — A Future Role for Combination Therapy},
journal = {New England Journal of Medicine},
year = {2024},
doi = {10.1056/nejme2406180}
}
EUVIMED